How much funding has Eluminex raised?

Eluminex has raised $90.0M in total funding, most recently a Series B round.

Who are Eluminex's investors?

Eluminex's investors include Cenova Capital, Lilly Asia Ventures, GL Ventures, Quan Capital, Guangzhou Yuexiu Industrial Investment Fund Management, 3E Bioventures Capital.

Where is Eluminex headquartered?

Eluminex is headquartered in Suzhou, China.

What industry is Eluminex in?

Eluminex operates in Biotech, Healthcare.

Eluminex

Suzhou, China · Founded 2020 · $90.0M raised

Biotech

Healthcare

Headquarters: Suzhou
Founded: 2020
Business Model: B2B
Website: eluminexbio.com

Total Funding: $90.0M
Last Round: $40.0M Series BFeb 2023
Rounds: 2

About

Eluminex Biosciences is an ophthalmic biotechnology company committed to discovering and developing first-in-class and best-in-class therapies for vision-threatening eye diseases. Founded in February 2020 by Dr. Jinzhong Zhang and Dr. Zhenze John Hu, the company is headquartered in Suzhou Industrial Park with a business center in Shanghai. Eluminex raised a $50 million Series A in November 2020 co-led by Lilly Asia Ventures, GL Ventures (Hillhouse Capital), and Quan Capital, targeting both China and global markets with its innovative ophthalmic pipeline.

Summary

Eluminex is a Biotech company based in Suzhou, China, founded in 2020. It has raised $90.0M in total across 2 rounds, most recently a $40.0M Series B round in Feb 2023. Investors include Cenova Capital, Lilly Asia Ventures and GL Ventures.